What
is the most important information I should know about rilpivirine?
Rilpivirine
is an experimental non-nucleoside reverse transcriptase inhibitor (NNRTI) being
developed by Tibotec, a biotechnology company in Belgium. It has not yet been
evaluated by the U.S. Food and Drug Administration (FDA) for use by people living
with HIV.
What
is rilpivirine?
Rilpivirine
is in a category of HIV medicines called non-nucleoside reverse transcriptase
inhibitors (NNRTIs). Rilpivirine prevents HIV from entering the nucleus of healthy
T-cells. This prevents the cells from producing new virus and decreases the amount
of virus in the body.